SARS-CoV-2 Antibody Test - India CDSCO Medical Device Registration

SARS-CoV-2 Antibody Test is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2020/000167_5b13e39dd159a6f75b63c2f8306d4824_76742064947f760a3a9b258dcae29cc8. This device is marketed under the brand name Lateral Flow Method. The license holder is MYLAN PHARMACEUTICALS PRIVATE LIMITED, and it is classified as Device Class Class C. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database

CDSCO Registered

Class Class C

SARS-CoV-2 Antibody Test

UID: IMP/IVD/2020/000167_5b13e39dd159a6f75b63c2f8306d4824_76742064947f760a3a9b258dcae29cc8

Brand Name

Lateral Flow Method

License Holder

MYLAN PHARMACEUTICALS PRIVATE LIMITED

Device Class

Class C

Approving Authority

CDSCO

Product Information

SARS-CoV-2 Antibody Test (Lateral Flow Method) is an immunochromatographic assay for rapid, Qualitative detection of Severe Acute Respiratory Syndrome Coronavirus 2 (Lateral Flow Method) IgG/IgM antibody in human whole blood, serum or plasma sample. The test is to be used as an aid in the diagnosis of coronavirus infection disease (Lateral Flow Method), which is caused by SARS-CoV-2. The test provides preliminary test results. Negative results don’t preclude SARS-CoV-2 infection and they cannot be used as the sole basis for treatment or other management decision. For in vitro diagnostic use only. For professional use only.

Class C